obesity drug news today glp-1 september 22 2025 New Guidelines on Drugs for Released ISPOR 2025: Exploring reasons for
Description
2012;30(3):e146e155
This is important for two reasons
People with type 2 diabetes using GLP-1 receptor agonists, DPP-IV inhibitors or multiple therapies combining metformin, sulfonylureas, repaglinide, alpha-glucosidase inhibitors or thiazolidinediones from 2006 to 2018 were included
doi: 10.2174/157488910791213130 85 HolscherC
& Mansoor, S
M.WuY.ThomasA
